Top

Current Hematologic Malignancy Reports

Published in:

01-04-2018 | Multiple Myeloma (P Kapoor, Section Editor)

Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies

Authors: Kristen B. McCullough, Miriam A. Hobbs, Jithma P. Abeykoon, Prashant Kapoor

Published in: Current Hematologic Malignancy Reports | Issue 2/2018

Abstract

Purpose of Review

The purpose of this review was to evaluate management strategies for common adverse effects of novel therapies in multiple myeloma (MM), including immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, and a histone deacetylase inhibitor.

Recent Findings

There are several adverse effects that occur across multiple classes of antimyeloma drugs, including rash, peripheral neuropathy, infusion reactions, and cardiotoxicity, but most can be managed without complete discontinuation of the agent or abandonment of the class. Additionally, several agents have critically important drug-drug interactions or dose-modification implications in hepatic or renal insufficiency that can be easily overlooked, and exacerbate adverse effects.

Summary

As treatment of MM moves from fixed-duration traditional chemotherapy to novel agent-based regimens, commonly administered continuously until disease progression or intolerable toxicities, providers must adopt their management strategies for both acute and long-term adverse effects. Early and frequent monitoring for therapy-related complications, dose adjustments when needed, and timely treatment for toxicities are all important steps toward ensuring longevity of treatment from a limited array of therapeutic options that currently exist for a disease with a relapsing and remitting course.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. https://doi.org/10.3322/caac.21387.CrossRefPubMed

•• Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207–19. https://doi.org/10.1056/NEJMoa1506348. Daratumumab is a human antibody approved for the treatment of relapsed/refractory multiple myeloma. This phase I study characterized efficacy while also outlining the important safety concerns related to infusion reactions. Subsequent studies have combined it with several different classes to provide prolonged survival opportunities.CrossRefPubMed

• Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, et al. Oral Ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621–34. https://doi.org/10.1056/NEJMoa1516282. This is the first all oral regimen for the treatment of relapsed/refractory mutiple myeloma and ixazomib is the first oral proteasome inhibitor.CrossRefPubMed

Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319–31. https://doi.org/10.1056/NEJMoa1607751.CrossRefPubMed

Celgene. REVLIMID® (lenalidomide) capsules, for oral use. Prescribing information. 2017. http://media.celgene.com/content/uploads/revlimid-pi.pdf. Accessed 13 Oct 2017.

Celgene. POMALYST® (pomalidomide) capsules, for oral use. Prescribing information. 2017. http://media.celgene.com/content/uploads/pomalyst-pi.pdf. Accessed 13 Oct 2017.

Celgene. THALOMID® (thalidomide) capsules, for oral use. Prescribing information. 2017. http://media.celgene.com/content/uploads/thalomid-pi.pdf. Accessed 13 Oct 2017.

Takeda. VELCADE® (bortezomib) for injection, for intravenous use. Prescribing information. 2017. http://www.velcade.com/files/PDFs/VELCADE_PRESCRIBING_INFORMATION.pdf. Accessed 13 Oct 2017.

Amgen. KYPROLIS® (carfilzomib) for injection, for intravenous use. Prescribing information. 2017. http://pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/kyprolis/kyprolis_pi.pdf. Accessed 13 Oct 2017.

10.

Takeda. NINLARO® (ixazomib) capsules, for oral use. Prescribing information. 2017. https://www.ninlaro.com/prescribing-information.pdf. Accessed 13 Oct 2017.

11.

Novartis. FARYDAK® (panobinostat) capsules, for oral use. Prescribing information. 2017. https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/farydak.pdf. Accessed 13 Oct 2017.

12.

Janssen. DARZALEX® (daratumumab) for injection, for intravenous use. Prescribing information. 2017. https://www.darzalex.com/sites/www.darzalex.com/files/darzalex-prescribing-information.pdf. Accessed 13 Oct 2017.

13.

Bristol-Myers Squibb. EMPLICITI® (elotuzumab) for injection, for intravenous use. Prescribing information 2017. https://packageinserts.bms.com/pi/pi_empliciti.pdf. Accessed 13 Oct 2017.

14.

Nardone B, Wu S, Garden BC, West DP, Reich LM, Lacouture ME. Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis. Clin Lymphoma Myeloma Leuk. 2013;13(4):424–9. https://doi.org/10.1016/j.clml.2013.03.006.CrossRefPubMed

15.

Sviggum HP, Davis MP, Rajkumar S, Dispenzieri A. Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Arch Dermatol. 2006;142(10):1298–302. https://doi.org/10.1001/archderm.142.10.1298.CrossRefPubMed

16.

Barley K, He W, Agarwal S, Jagannath S, Chari A. Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma. Leuk Lymphoma. 2016;57(11):2510–5. https://doi.org/10.3109/10428194.2016.1151507.CrossRefPubMed

17.

Tinsley SM, Kurtin SE, Ridgeway JA. Practical management of lenalidomide-related rash. Clin Lymphoma Myeloma Leuk. 2015;15(Suppl):S64–9. https://doi.org/10.1016/j.clml.2015.02.008.CrossRefPubMed

18.

Lee MJ, Wickner P, Fanning L, Schlossman R, Richardson P, Laubach J, et al. Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma. Br J Haematol. 2014;167(1):127–31. https://doi.org/10.1111/bjh.12925.CrossRefPubMed

19.

Seki JT, Sakurai N, Lam W, Reece DE. Pomalidomide desensitization in a patient hypersensitive to immunomodulating agents. Curr Oncol. 2017;24(4):e328–e32. https://doi.org/10.3747/co.24.3572.CrossRefPubMedPubMedCentral

20.

Cavaletti G, Jakubowiak AJ. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk Lymphoma. 2010;51(7):1178–87. https://doi.org/10.3109/10428194.2010.483303.CrossRefPubMed

21.

Voorhees PM, Laubach J, Anderson KC, Richardson PG. Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy. Blood. 2013;121(5):858. https://doi.org/10.1182/blood-2012-11-465765.CrossRefPubMedPubMedCentral

22.

Delforge M, Blade J, Dimopoulos MA, Facon T, Kropff M, Ludwig H, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol. 2010;11(11):1086–95. https://doi.org/10.1016/s1470-2045(10)70068-1.CrossRefPubMed

23.

Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O, et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia. 2012;26(4):595–608. https://doi.org/10.1038/leu.2011.346.CrossRefPubMed

24.

Dimopoulos MA, Mateos MV, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol. 2011;86(1):23–31. https://doi.org/10.1111/j.1600-0609.2010.01533.x.CrossRefPubMed

25.

Broyl A, Corthals SL, Jongen JL, van der Holt B, Kuiper R, de Knegt Y, et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol. 2010;11(11):1057–65. https://doi.org/10.1016/s1470-2045(10)70206-0.CrossRefPubMed

26.

Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431–40. https://doi.org/10.1016/s1470-2045(11)70081-x.CrossRefPubMed

27.

Merz M, Salwender H, Haenel M, Mai EK, Bertsch U, Kunz C, et al. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. Haematologica. 2015;100(7):964–9. https://doi.org/10.3324/haematol.2015.124347.CrossRefPubMedPubMedCentral

28.

Hu B, Zhou Q, Wu T, Zhuang L, Yi L, Cao J, et al. Efficacy and safety of subcutaneous versus intravenous bortezomib in multiple myeloma: a meta-analysis. Int J Clin Pharmacol Ther. 2017;55(4):329–38. https://doi.org/10.5414/cp202714.CrossRefPubMed

29.

Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009;144(6):895–903. https://doi.org/10.1111/j.1365-2141.2008.07573.x.CrossRefPubMed

30.

Hashimoto N, Yokoyama K, Sadahira K, Ueda T, Tsukada Y, Okamoto S. Itraconazole may increase the risk of early-onset bortezomib-induced peripheral neuropathy. Int J Hematol. 2012;96(6):758–63. https://doi.org/10.1007/s12185-012-1224-5.CrossRefPubMed

31.

Bringhen S, Larocca A, Rossi D, Cavalli M, Genuardi M, Ria R, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010;116(23):4745–53. https://doi.org/10.1182/blood-2010-07-294983.CrossRefPubMed

32.

Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013;98(11):1753–61. https://doi.org/10.3324/haematol.2013.089334.CrossRefPubMedPubMedCentral

33.

Mileshkin L, Prince HM. The troublesome toxicity of peripheral neuropathy with thalidomide. Leuk Lymphoma. 2006;47(11):2276–9. https://doi.org/10.1080/10428190600948303.CrossRefPubMed

34.

• Delforge M, Ludwig H. How I manage the toxicities of myeloma drugs. Blood. 2017;129(17):2359–67. https://doi.org/10.1182/blood-2017-01-725705. This case-based review of toxicity management for current providers in multiple myeloma includes newer agents and a range of toxicities.CrossRefPubMed

35.

San Miguel J, Weisel K, Moreau P, Lacy M, Song K, Delforge M, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(11):1055–66. https://doi.org/10.1016/s1470-2045(13)70380-2.CrossRef

36.

Dimopoulos MA, Palumbo A, Corradini P, Cavo M, Delforge M, Di Raimondo F, et al. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood. 2016;128(4):497–503. https://doi.org/10.1182/blood-2016-02-700872.CrossRefPubMedPubMedCentral

37.

Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009;23(11):2147–52. https://doi.org/10.1038/leu.2009.147.CrossRefPubMed

38.

Beijers AJ, Jongen JL, Vreugdenhil G. Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies. Neth J Med. 2012;70(1):18–25.PubMed

39.

Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941–67. https://doi.org/10.1200/jco.2013.54.0914.CrossRefPubMed

40.

Jongen JL, Broijl A, Sonneveld P. Chemotherapy-induced peripheral neuropathies in hematological malignancies. J Neuro-Oncol. 2015;121(2):229–37. https://doi.org/10.1007/s11060-014-1632-x.CrossRef

41.

Cartoni C, Brunetti GA, Federico V, Efficace F, Grammatico S, Tendas A, et al. Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma. Support Care Cancer. 2012;20(10):2621–6. https://doi.org/10.1007/s00520-012-1511-y.CrossRefPubMed

42.

Barton DL, Wos EJ, Qin R, Mattar BI, Green NB, Lanier KS, et al. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer. 2011;19(6):833–41. https://doi.org/10.1007/s00520-010-0911-0.CrossRefPubMed

43.

Bao T, Goloubeva O, Pelser C, Porter N, Primrose J, Hester L, et al. A pilot study of acupuncture in treating bortezomib-induced peripheral neuropathy in patients with multiple myeloma. Integr Cancer Ther. 2014;13(5):396–404. https://doi.org/10.1177/1534735414534729.CrossRefPubMedPubMedCentral

44.

Pittler MH, Ernst E. Complementary therapies for neuropathic and neuralgic pain: systematic review. Clin J Pain. 2008;24(8):731–3. https://doi.org/10.1097/AJP.0b013e3181759231.CrossRefPubMed

45.

Leleu X, Rodon P, Hulin C, Daley L, Dauriac C, Hacini M, et al. MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs. Thromb Haemost. 2013;110(4):844–51. https://doi.org/10.1160/th13-02-0140.PubMed

46.

Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22(2):414–23. https://doi.org/10.1038/sj.leu.2405062.CrossRefPubMed

47.

Kamat AV. Rivaroxaban is an effective and well tolerated anti thrombotic agent in patients on lenalidomide therapy and in multiple myeloma. Blood. 2014;124(21):5095.

48.

Oka S, Takeuchi S, Shiragami H, Hamahata K, Nohgawa M. Successful management of venous thromboembolism with apixaban in a multiple myeloma patient on lenalidomide therapy. Rinsho Ketsueki. 2017;58(1):37–41. https://doi.org/10.11406/rinketsu.58.37.PubMed

49.

Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol. 2011;29(8):986–93. https://doi.org/10.1200/jco.2010.31.6844.CrossRefPubMed

50.

Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017;35(28):3240–61. https://doi.org/10.1200/jco.2017.74.4789.CrossRefPubMed

51.

National Cancer Center Network. Antiemesis (Version 2.2017). https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. Accessed 13 Oct 2017.

52.

• San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15(11):1195–206. https://doi.org/10.1016/s1470-2045(14)70440-1. Panobinostat is the only histone deacetylase inhibitor approved for the treatment of multiple myeloma. This agent has a notably unique drug interaction and adverse effect profile.CrossRefPubMed

53.

Pawlyn C, Khan MS, Muls A, Sriskandarajah P, Kaiser MF, Davies FE, et al. Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment. Blood. 2014;124(15):2467–8. https://doi.org/10.1182/blood-2014-06-583302.CrossRefPubMed

54.

Watson M, Nooka AK, Gleason C, Valla K, Kaufman JL, Lonial S. Colesevelam hydrochloride for the treatment of Lenalidomide induced diarrhea. Blood. 2014;124(21):5779.

55.

Lenihan DJ, Potluri R, Bhandari H, Ranjan S, Chen C. Evaluation of cardiovascular comorbidities among patients with multiple myeloma in the United States. Blood. 2016;128(22):4794.

56.

Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc. 2014;89(9):1287–306. https://doi.org/10.1016/j.mayocp.2014.05.013.CrossRefPubMedPubMedCentral

57.

Chow EJ, Wong K, Lee SJ, Cushing-Haugen KL, Flowers ME, Friedman DL, et al. Late cardiovascular complications after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20(6):794–800. https://doi.org/10.1016/j.bbmt.2014.02.012.CrossRefPubMedPubMedCentral

58.

Grandin EW, Ky B, Cornell RF, Carver J, Lenihan DJ. Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma. J Card Fail. 2015;21(2):138–44. https://doi.org/10.1016/j.cardfail.2014.11.008.CrossRefPubMed

59.

Xiao Y, Yin J, Wei J, Shang Z. Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis. PLoS One. 2014;9(1):e87671. https://doi.org/10.1371/journal.pone.0087671.CrossRefPubMedPubMedCentral

60.

Atrash S, Tullos A, Panozzo S, Bhutani M, Van Rhee F, Barlogie B, et al. Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib. Blood Cancer J. 2015;5(1):e272. https://doi.org/10.1038/bcj.2014.93.CrossRefPubMedPubMedCentral

61.

Dimopoulos MA, Roussou M, Gavriatopoulou M, Psimenou E, Ziogas D, Eleutherakis-Papaiakovou E, et al. Cardiac and renal complications of carfilzomib in patients with multiple myeloma. Blood Adv. 2017;1(7):449–54. https://doi.org/10.1182/bloodadvances.2016003269.CrossRefPubMedPubMedCentral

62.

Waxman AJ, Clasen S, Hwang WT, Garfall A, Vogl DT, Carver J, et al. Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis. JAMA Oncol. 2017:e174519. https://doi.org/10.1001/jamaoncol.2017.4519.

63.

Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(10):1327–37. https://doi.org/10.1016/s1470-2045(17)30578-8.CrossRefPubMed

64.

Jain T, Narayanasamy H, Mikhael J, Reeder CB, Bergsagel PL, Mayo A, et al. Reversible cardiotoxicity associated with carfilzomib use in patients with multiple myeloma. Blood. 2016;128(22):2126.

65.

Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754–66. https://doi.org/10.1056/NEJMoa1606038.CrossRefPubMed

66.

Chari A, Suvannasankha A, Fay JW, Arnulf B, Kaufman JL, Ifthikharuddin JJ, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. 2017;130(8):974–81. https://doi.org/10.1182/blood-2017-05-785246.CrossRefPubMedPubMedCentral

67.

Chari A, Mark TM, Krishnan A, Stockerl-Goldstein K, Usmani SZ, Londhe A, et al. Use of montelukast to reduce infusion reactions in an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. Blood. 2016;128(22):2142.

68.

Nahi H, Hellemans P, Masterson TJ, Clemens PL, Ahmadi T, Miguel JS, et al. An open-label, dose-escalation phase 1b study of subcutaneous daratumumab with recombinant human hyaluronidase in patients with relapsed or refractory multiple myeloma (PAVO). J Clin Oncol. 2016;34(15_suppl):TPS8071–TPS. https://doi.org/10.1200/JCO.2016.34.15_suppl.TPS8071.

69.

Zonder JA, Mohrbacher AF, Singhal S, van Rhee F, Bensinger WI, Ding H, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood. 2012;120(3):552–9. https://doi.org/10.1182/blood-2011-06-360552.CrossRefPubMedPubMedCentral

70.

• Dimopoulos MA, Lonial S, White D, Moreau P, Palumbo A, San-Miguel J, et al. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol. 2017;178(6):896–905. https://doi.org/10.1111/bjh.14787. A humanized monoclonal antibody for relapsed/refractory multiple myeloma with fewer infusion reactions than its counterpart, but evidence of prolonged progression free survival.CrossRefPubMed

71.

Harvey RD. Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib. Clin Pharmacol. 2014;6:87–96. https://doi.org/10.2147/CPAA.S62512.PubMedPubMedCentral

72.

Jakubowiak AJ. Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview. Cancer Treat Rev. 2014;40(6):781–90. https://doi.org/10.1016/j.ctrv.2014.02.005.CrossRefPubMed

73.

Finnes HD, Kumar S, LaPlant B, Gertz MA, Buadi F, Lacy M, et al. Importance of pharmacovigilance in the era of small molecules: role of pharmacist consultation with ixazomib (IXA) in multiple myeloma (MM). J Clin Oncol. 2016;34(15_suppl):8058. https://doi.org/10.1200/JCO.2016.34.15_suppl.8058.

Title: Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies
Authors: Kristen B. McCullough
Miriam A. Hobbs
Jithma P. Abeykoon
Prashant Kapoor
Publication date: 01-04-2018
Publisher: Springer US
Published in: Current Hematologic Malignancy Reports / Issue 2/2018
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI: https://doi.org/10.1007/s11899-018-0443-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 2/2018

Prognostic Factors in the Era of Targeted Therapies in CLL

Managing the Mental Distress of the Hematopoietic Stem Cell Transplant (HSCT) Patient: a Focus on Delirium

Frontline Therapy of CLL: Evolving Treatment Paradigm

Update on the Treatment of Anaplastic Large Cell Lymphoma

Value-Based Care in Hematopoietic Cell Transplantation and Cellular Therapy: Challenges and Opportunities

Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials